BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11821451)

  • 1. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?
    Ursin G; Tseng CC; Paganini-Hill A; Enger S; Wan PC; Formenti S; Pike MC; Ross RK
    J Clin Oncol; 2002 Feb; 20(3):699-706. PubMed ID: 11821451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.
    Pike MC; Ross RK
    Steroids; 2000; 65(10-11):659-64. PubMed ID: 11108873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk.
    Tan DA; Dayu ARB
    Climacteric; 2022 Aug; 25(4):362-368. PubMed ID: 35147073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.
    Lancet; 1997 Oct; 350(9084):1047-59. PubMed ID: 10213546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
    Wang SM; Pfeiffer RM; Gierach GL; Falk RT
    Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for in situ breast cancer.
    Longnecker MP; Bernstein L; Paganini-Hill A; Enger SM; Ross RK
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):961-5. PubMed ID: 8959317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.
    Rosenberg LU; Granath F; Dickman PW; Einarsdóttir K; Wedrén S; Persson I; Hall P
    Breast Cancer Res; 2008; 10(5):R78. PubMed ID: 18803850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast tumours following combined hormone replacement therapy express favourable prognostic factors.
    Borgquist S; Anagnostaki L; Jirström K; Landberg G; Manjer J
    Int J Cancer; 2007 May; 120(10):2202-7. PubMed ID: 17278089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormone replacement therapy in menopause and risk of breast cancer].
    Clavel-Chapelon F; Hill C
    Presse Med; 2000 Oct; 29(31):1688-93. PubMed ID: 11094609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal estrogen and progestin use in relation to breast cancer risk.
    Newcomb PA; Titus-Ernstoff L; Egan KM; Trentham-Dietz A; Baron JA; Storer BE; Willett WC; Stampfer MJ
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):593-600. PubMed ID: 12101105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risk: effects of estrogen replacement therapy and body mass.
    Harris RE; Namboodiri KK; Wynder EL
    J Natl Cancer Inst; 1992 Oct; 84(20):1575-82. PubMed ID: 1404451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of hormone replacement therapy on blood serum lipids in postmenopausal women with type 2 diabetes].
    Kozlov SG; Dotsenko IuV; Sankova AV; Liakishev AA; Tvorogova MG; Afanas'eva OI; Titov VN; Pokrovskiĭ SN; Naumov VG
    Kardiologiia; 2002; 42(7):47-52. PubMed ID: 12494113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menopausal hormone therapy and risk of clinical breast cancer subtypes.
    Slanger TE; Chang-Claude JC; Obi N; Kropp S; Berger J; Vettorazzi E; Braendle W; Bastert G; Hentschel S; Flesch-Janys D
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1188-96. PubMed ID: 19336542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and breast cancer: revisiting the issues.
    DeGregorio MW; Taras TL
    J Am Pharm Assoc (Wash); 1998; 38(6):738-44; quiz 744-6. PubMed ID: 9861792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
    Li CI; Malone KE; Daling JR
    Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
    Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
    J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.